We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

Treasury and Payments

Improve your working capital, reduce fraud and minimize the impact of unexpected disruptions with our treasury solutions—from digital portals to integrated payables and receivables—all designed to make your operations smoother and more efficient.

Learn more about our treasury solutions:

Credit and Financing

Prepare for future growth with customized loan services, succession planning and capital for business equipment or technology.

Learn more about our credit and financing solutions:

Commercial Real Estate

Get the strategic support to be successful throughout market and real estate cycles with insights, hands-on service, comprehensive financial solutions and unrivaled certainty of execution.

Learn more about our commercial real estate solutions:

International Banking

Global opportunities mean global challenges. But real success means understanding the local markets you serve—which is why we bring the business solutions, insights and market perspective you need. 

Learn more about our international banking solutions:

Newsletter

Discover the latest numbers, news and market moves to know about each week with Ginger Chambless, Commercial Banking’s Head of Research.

Life Sciences

Life sciences still going strong as 2022 begins

Our Biopharma and Medtech Deals and Funding report offers insights on upfront cash, IPOs, potential acquisitions and other trends.


Dealmaking across the life sciences sector continued to break records in 2021. Biopharma therapeutics and discovery platform companies led the way in licensing and venture attraction, and medtech activity remained above its pre-pandemic levels.

J.P. Morgan’s Biopharma and Medtech Deals and Funding outlook report looks back at activity in the previous year to provide insights on industry trends we might see in 2022. The report, powered by DealForma, highlights:

  • R&D partnerships: The number of deals fell slightly last year, coming off an abundance of activity in 2020 fueled largely by the COVID-19 crisis.
  • Upfront cash: Despite the pandemic driving record revenues for top pharma companies, upfront cash dropped $6 billion in 2021.
  • Preclinical IPOs: These offerings are becoming more common as companies go public sooner in their development timeline.
  • Biopharma venture investment: Funding through 2021 hit $39 billion, surpassing the $26 billion raised in 2020.
  • Potential acquisitions: Combined with end-of-the-year deals and licenses, the amount of cash in the market has set the stage for more acquisitions in 2022.
Technology and Disruptive Commerce Healthcare Life Sciences Annual Outlook Treasury Services Startups Liquidity Management Trends

Get in Touch and Stay Informed

icon
Loading...